Clinical Trials
54 trialsA Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Bristol-Myers Squibb
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
Shattuck Labs, Inc.
Doxil/Caelyx BE Study
Baxter Healthcare Corporation
Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer
North Eastern German Society of Gynaecological Oncology
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Mayo Clinic
PEMBOV
Gustave Roussy, Cancer Campus, Grand Paris
ANITA
Grupo Español de Investigación en Cáncer de Ovario
SGI-110
Astex Pharmaceuticals, Inc.
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
Arcus Biosciences, Inc.
MYCA
ARCAGY/ GINECO GROUP
JAVELIN Ovarian 200
Pfizer
Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Aravive, Inc.
Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
Ludwig Institute for Cancer Research
Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
Dana-Farber Cancer Institute
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
Hoffmann-La Roche
INOVATYON
Mario Negri Institute for Pharmacological Research
MITO23
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
FORWARD I
ImmunoGen, Inc.
CORAIL
PharmaMar
ICEBERG 3
AstraZeneca
Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer
Bayer
Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer
NYU Langone Health
A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
Eli Lilly and Company
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Janssen Research & Development, LLC
EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Real-World Effectiveness of PLD in Platinum- Sensitive Recurrent Ovarian Cancer
Konkuk University Medical Center
NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)
AGC Biologics S.p.A.
REBECA
Yonsei University
NGR018
AGC Biologics S.p.A.
A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer
AbbVie
Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
National Cancer Institute (NCI)
Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer
GlaxoSmithKline
A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)
Merck Sharp & Dohme LLC
A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)
Merck Sharp & Dohme LLC
Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer
Novo Nordisk A/S
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Santa Maria Biotherapeutics
A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
Janssen Research & Development, LLC
Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
PITCH
Leiden University Medical Center
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
Janssen Research & Development, LLC
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
Amgen
BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer
Boehringer Ingelheim
Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)
New Mexico Cancer Research Alliance
Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED)
Merck Sharp & Dohme LLC
PRECEDENT
Endocyte
An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CALYPSO
ARCAGY/ GINECO GROUP
Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)
AbbVie
S9912 Combination Chemo in Stage III Ovarian Cancer,
SWOG Cancer Research Network